Why the study?
Does fosinopril reduce PAI-1 antigen compared to amlodipine in patients with hypertension and type 2 diabetes mellitus?
Does fosinopril reduce PAI-1 antigen compared to amlodipine in patients with hypertension and type 2 diabetes mellitus?
Fosinopril reduces PAI-1 antigen levels compared to amlodipine in patients with hypertension and type 2 diabetes, suggesting a potential mechanism for improved clinical outcomes with ACE inhibitors.
No takes yet. Share an insight, caveat, or question.
May favor ACE inhibitors over CCBs in hypertensive T2DM to reduce thrombotic risk; extends evidence for class-specific fibrinolytic effects.
Pahor et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: